MedPath

Jiangmen Central Hospital

🇨🇳China
Ownership
-
Established
1912-01-01
Employees
-
Market Cap
-
Website
http://www.bjch.com/

Clinical Trials

3

Active:0
Completed:0

Trial Phases

2 Phases

Phase 2:2
Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 4
1 (33.3%)

Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma

Phase 2
Conditions
Advanced Cholangiocarcinoma
Interventions
Drug: 5- fluorine pyrimidine
First Posted Date
2019-06-11
Last Posted Date
2019-07-16
Lead Sponsor
Jiangmen Central Hospital
Target Recruit Count
30
Registration Number
NCT03982680
Locations
🇨🇳

Jiangmen central hospital, Jiangmen, Guangdong, China

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Phase 2
Conditions
Breast Cancer
Interventions
First Posted Date
2012-11-22
Last Posted Date
2012-12-03
Lead Sponsor
Jiangmen Central Hospital
Target Recruit Count
50
Registration Number
NCT01732276

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.